Course of disease in patients with microscopic colitis - a European prospective incident cohort study

  • Bas P M Verhaegh
  • Andreas Münch
  • Danila Guagnozzi
  • Signe Wildt
  • W Cebula
  • A R Diac
  • Fernando Fernández-Bañares
  • M A R Al-Khalaf
  • N Pedersen
  • Juozas Kupcinskas
  • Johan Bohr
  • Gilles Macaigne
  • Alfredo J Lucendo
  • Ivan Lyutakov
  • Gian-Eugenio Tontini
  • Flavia Pigò
  • E Russo
  • Henrik Hjortswang
  • Stephan Miehlke
  • Lars K Munck

Abstract

BACKGROUND AND AIMS: The disease course of microscopic colitis [MC] is considered chronic but benign. However, this assumption is based on mainly retrospective studies, reporting on incomplete follow-up of selective cohorts. Systematic, prospective and unbiased data to inform patients and healthcare professionals on the expected course of the disease and real-life response to therapy are warranted.

METHODS: A prospective, pan-European, multi-centre, web-based registry was established. Incident cases of MC were included. Data on patient characteristics, symptoms, treatment and quality of life were systematically registered at baseline and during real-time follow-up. Four disease course phenotypes were discriminated and described.

RESULTS: Among 381 cases with complete 1-year follow-up, 49% had a chronic active or relapsing disease course, 40% achieved sustained remission after treatment and 11% had a quiescent course. In general, symptoms and quality of life improved after 3 months of follow-up. A relapsing or chronic active disease course was associated with significantly more symptoms and impaired quality of life after 1 year.

CONCLUSIONS: A minority of MC patients follow a quiescent disease course with spontaneous clinical improvement, whereas the majority suffer a chronic active or relapsing disease course during the first year after diagnosis, with persisting symptoms accompanied by a significantly impaired quality of life.

Bibliographical data

Original languageEnglish
ISSN1873-9946
DOIs
Publication statusPublished - 05.07.2021
PubMed 33433605